Trevi Therapeutics Stock Price, News & Analysis

Trevi Therapeutics, Inc. (Nasdaq: TRVI) announced a virtual R&D Day scheduled for September 19, 2022, from 10 AM to 12:30 PM ET. The event will feature expert presentations from Dr. Peter Dicpinigaitis and Dr. Brian Kim, focusing on chronic cough and prurigo nodularis. Trevi will provide updates on its investigational therapy Haduvio (oral nalbuphine ER), which aims to address unmet needs in these conditions. Participants can register and access a live webcast of the event.

Trevi Therapeutics, Inc. (TRVI) announced that two late-breaking abstracts have been accepted for oral presentations at upcoming medical conferences. The European Respiratory Society International Congress 2022, held in Barcelona from September 4-6, will feature data from the Phase 2 CANAL trial on the use of Haduvio™ (oral nalbuphine ER) for chronic cough in idiopathic pulmonary fibrosis (IPF). Similarly, the EADV Congress in Milan from September 7-10 will present findings from the Phase 2b/3 PRISM trial on prurigo nodularis. Both trials reported statistically significant efficacy results.

Trevi Therapeutics reported positive results from the Phase 2b/3 PRISM trial of its investigational therapy, Haduvio™, for treating Prurigo Nodularis. The trial achieved its primary endpoint, with 25% of Haduvio patients showing a significant reduction in itch compared to 14% on placebo (p=0.0157). The company completed a $55 million private placement to support further clinical development. For Q2 2022, Trevi's total cash was $78.9 million, with a net loss of $8.1 million, improved from $9.8 million in Q2 2021.

Future data from the Phase 2 CANAL trial on chronic cough is expected later this quarter.

Trevi Therapeutics, Inc. (NASDAQ: TRVI) announced its participation in two key conferences in August 2022. On August 16, CEO Jennifer Good will engage in a fireside chat at the Stifel Biotech Executive Summer Summit. On August 29, CMO Thomas Sciascia and Professor Toby Maher will co-host a workshop at the 6th Annual IPF Summit in Boston, emphasizing chronic cough treatment strategies. Trevi's investigational therapy Haduvio is being developed for prurigo nodularis and chronic cough in adults with idiopathic pulmonary fibrosis, with FDA Fast Track designation for itch treatment.

Trevi Therapeutics (Nasdaq: TRVI) will host a conference call and live audio webcast on August 11, 2022, at 4:30 p.m. ET, to discuss its Q2 2022 financial results and provide a corporate update. The company is developing Haduvio (oral nalbuphine ER) as a treatment for prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis. Haduvio has received FDA Fast Track designation for the treatment of itch. More information can be accessed on the company’s website.

Trevi Therapeutics (Nasdaq: TRVI), a clinical-stage biopharmaceutical company, will participate in The Twelfth London International Cough Symposium on July 13-14, 2022. The event will focus on advancements related to acute and chronic cough, including novel treatments. Trevi is developing Haduvio (oral nalbuphine ER) aimed at treating prurigo nodularis and chronic cough in idiopathic pulmonary fibrosis patients. Haduvio has received Fast Track designation from the FDA for reducing pruritus in affected adults, though its efficacy is yet to be evaluated by regulatory authorities.

Trevi Therapeutics (TRVI) announced positive results from its Phase 2b/3 PRISM trial evaluating Haduvio for treating prurigo nodularis. The trial achieved statistical significance with a 4-point reduction in the Worst Itch – Numerical Rating Scale (WI-NRS) for 25% of Haduvio patients compared to 14% for placebo (p=0.0157). Key secondary endpoints were also met. The drug's safety profile was consistent with prior studies. Topline results will be discussed in a conference call on June 29, 2022, at 8:30 am EDT, highlighting Haduvio's potential in addressing severe itching and enhancing quality of life.

Trevi Therapeutics, Inc. (Nasdaq: TRVI) announced that its President and CEO, Jennifer Good, will present at the 2022 BIO International Convention on June 13 at 4 PM PT in San Diego, CA. The convention is expected to attract over 15,000 leaders in biotechnology and pharma, focusing on networking and partnership opportunities. Trevi is developing Haduvio™, an investigational therapy for pruritus in prurigo nodularis and chronic cough in idiopathic pulmonary fibrosis, and is currently conducting Phase 2b/3 and Phase 2 clinical trials for these conditions.

Trevi Therapeutics, Inc. (Nasdaq: TRVI) announced significant advancements in its clinical development for Haduvio, targeting chronic cough in idiopathic pulmonary fibrosis (IPF) and chronic pruritus in prurigo nodularis (PN). The Phase 2 CANAL trial demonstrated a 77.3% reduction in cough frequency, leading to expedited development. The company completed a private placement raising $55 million to fund further clinical trials. As of March 31, 2022, Trevi reported $29.1 million in cash and cash equivalents and a net loss of $7.3 million for the quarter.